GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
10 October 2023 - 7:05AM
GeneDx (Nasdaq: WGS), a leader in delivering improved health
outcomes through genomic and clinical insights, today announced it
will release financial results for the third quarter of 2023 after
the market closes on Monday, October 30, 2023. On the same day,
Katherine Stueland, President and Chief Executive Officer of
GeneDx, and Kevin Feeley, Chief Financial Officer of GeneDx, will
host a conference call to discuss financial and operating results
at 4:30 p.m. Eastern Time.
Conference Call Details
Investors interested in listening to the
conference call are required to register online. A live and
archived webcast of the event will be available on the “Events”
section of the GeneDx investor relations website at
https://ir.genedx.com/.
About GeneDx
GeneDx (Nasdaq: WGS) delivers personalized and
actionable health insights to inform diagnosis, direct treatment
and improve drug discovery. The company is uniquely positioned to
accelerate the use of genomic and large-scale clinical information
to enable precision medicine as the standard of care. GeneDx is at
the forefront of transforming healthcare through its
industry-leading exome and genome testing and interpretation,
fueled by one of the world’s largest rare disease data sets. For
more information, please visit genedx.com and connect with us on
LinkedIn, Facebook, and Instagram.
Investor Relations Contact:Tricia
Truehartinvestors@GeneDx.com
Media Contact:Teca Lewellynpress@GeneDx.com
GeneDx (NASDAQ:WGS)
Historical Stock Chart
From Apr 2024 to May 2024
GeneDx (NASDAQ:WGS)
Historical Stock Chart
From May 2023 to May 2024